Share/Bookmark

GCOM 2017 (Global Conference on Myositis)

May 5th-8th, 2017‚Äč | Potomac, Maryland, USA

Medical Conference Group Photo

Over 100 healthcare professionals attended the JM pre-conference workshop hosted by Cure JM.

On May 5-8, 2017, over 300 Myositis researchers from around the world came together in Potomac, MD for the 2nd Global Conference on Myositis (GCOM), sponsored in part by Cure JM Foundation. The goal of this four-day conference was to bring together Myositis researchers to advance the field of Myositis research through international collaboration.

On Friday, May 5, Cure JM hosted a workshop on Juvenile Myositis, with moderators Dr. Annett van Royen-Kerkhof and Cure JM Medical Advisory Board Member, Dr. Susan Kim.

Over 100 healthcare professionals attended the workshop to hear talks on important new developments in areas of research pertaining to juvenile myositis including An Update on Pathogenesis of Juvenile Dermatomyositis, Muscle Biopsies and Biomarkers and What They Tell Us About Juvenile Myositis Prognosis, The Interferonopathies and Their Relationship to JDM, and Lessons from the Non-Inflammatory Hereditable Myopathies.

On Saturday, May 6, Cure JM Executive Director James Minow and Cure JM Medical Advisory Board Members, Dr. Lisa Rider and Dr. Adam Huber, chaired a special Cure JM sponsored session where Cure JM Medical Advisory Board Members - and JM thought leaders - Dr. Lucy Wedderburn, Dr. Lauren Pachman, Dr. Ann Reed, and Dr. Brian Feldman, presented their perspectives on the current state and future priorities for research in JM. They all underscored the urgent need for increased collaboration across disciplines, centers, and borders.

Cure JM President Mitali Dave then presented the top 20 research priorities of Cure JM families with finding a cure, developing better treatments with less side effects, and identifying triggers for flare topping the list.

The audience of ˜75 researchers and Cure JM parents split up to brainstorm priorities for four areas of research: basic, clinical, translational, and underlying methodologies / resources.

“Together, researchers and patient families identified priorities for future research for the JM research community. I am thrilled that the research priorities took into account what matters most to Cure JM families,” says Annie Mitchell, Cure JM Board of Directors and member of the GCOM Steering Committee.

View Cure JM GCOM 2017 Highlights